BioSpace News Archive

- Average Daily Testing in January 2021 to Date Up 158% Over December 2020, Driven Primarily by Scale Up in Testing Contracts - - Company Increases Production of Assay Kits (Tests) and Sample Collection Kits to Meet Further Demand -

Salarius Pharmaceuticals, Inc. announced that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference.

Syntekabio (KOSDAQ: 226330), an AI and NGS-based drug development company, announced that it has signed multiple co-development agreement on 14th January with Hanmi Science (KOSPI: 008930) to develop COVID-19 treatments utilzing drug repositioning technologies.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Tuesday, January 19, 2021 at 1:00 pm Eastern Time.

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Henrietta Ukwu, M.D., FACP, FRAPS, to the position of Senior Vice President, Chief Regulatory and Quality Officer.

Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced the publication of a paper entitled, Hierarchical Bayesian modelling of disease progression to inform clinical trial design in centronuclear myopathy (CNM).

Steba biotech, pioneering developer of the IMmune Photo Activate Cancer Treatment (ImPACT), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for padeliporfin ImPACT for the treatment of adult patients with low-grade and unifocal high-grade Upper Tract Urothelial Cancer (UTUC)

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a Phase 4 study of VBI’s prophylactic 3-antigen hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier

AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination with IMFINZI® (durvalumab),

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patients in its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder.